Associations of the -238(G/A) and -308(G/A) TNF-α Promoter Polymorphisms and TNF-α Serum Levels with the Susceptibility to Gastric Precancerous Lesions and Gastric Cancer Related to Helicobacter pylori Infection in a Moroccan Population.
Adult
Biomarkers, Tumor
/ analysis
Case-Control Studies
Female
Follow-Up Studies
Gene Expression Regulation, Neoplastic
Genetic Predisposition to Disease
Helicobacter Infections
/ complications
Helicobacter pylori
/ isolation & purification
Humans
Male
Middle Aged
Morocco
/ epidemiology
Polymorphism, Single Nucleotide
Precancerous Conditions
/ blood
Prognosis
Promoter Regions, Genetic
Stomach Neoplasms
/ blood
Tumor Necrosis Factor-alpha
/ blood
Helicobacter pylori.
TNFα polymorphisms
TNFα serum levels
gastric carcinogenesis
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Jun 2020
01 Jun 2020
Historique:
received:
30
09
2019
entrez:
28
6
2020
pubmed:
28
6
2020
medline:
12
2
2021
Statut:
epublish
Résumé
Helicobacter pylori (H. pylori) induces the production of tumor necrosis factor-alpha (TNF-α), which is closely related to a gastric epithelial injury. TNF-α gene polymorphism and TNF-α serum levels are associated with various malignant conditions. Identification of the ideal marker for gastric cancer (GC) is still the leading aim of several trials. Physio-pathological considerations of GC led us to investigate the association of two TNF-α promoter polymorphisms (-308G>A and -238G>A), and TNF-α serum levels with the susceptibility to gastric precancerous (PL) and GC. Patients suffering from gastric lesions (65 chronic gastritis, 50 PL, 40 GC) related to H. pylori infection , and 63 healthy controls (HC) were involved in this study. Individuals are genotyped by TNF-α gene promoter sequencing and TNF-α serum levels are measured by ELISA quantitative method. Regarding TNF-α-308 G/A locus, we noticed higher risk for GC (OR=4.3, CI 1.5-11.9, p-value=0.005) and PL (OR=3.4, CI 1.2-9.2, p-value=0.01) for individuals with AA/GA genotypes compared to GG genotype. Concerning TNF-α-238 G/A locus, we noticed higher risk for GC (OR=5.9, CI 1.2-27.5, p-value=0.01) and PL (OR=4.8, CI 1.3-18, p-value=0.01) for individuals with GG genotype compared to AA/GA genotypes. We noticed that TNF-α serum levels have been increased together with gastric lesions severity. Moreover, TNF-α-308 and TNF-α-238 A alleles seemed to, respectively, upregulate and downregulate TNF-α serum levels. The TNF-α -308 A allele has a promotive effect for GC progression, whereas the TNF-α -238 A allele has a protective function against GC progression. High levels of TNF-α seemed to be associated with the aggressiveness of gastric lesions. TNF-α gene polymorphisms and TNF-α serum levels might be helpful to select those patients who are at high risk for GC.
Identifiants
pubmed: 32592356
doi: 10.31557/APJCP.2020.21.6.1623
pmc: PMC7568906
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1623-1629Références
Int J Biol Markers. 2004 Apr-Jun;19(2):130-4
pubmed: 15255545
Biomed Res Int. 2018 May 21;2018:3148137
pubmed: 29951534
J Transl Med. 2018 Aug 31;16(1):242
pubmed: 30170620
J Chin Med Assoc. 2003 Oct;66(10):593-8
pubmed: 14703276
Asian Pac J Cancer Prev. 2012;13(11):5777-83
pubmed: 23317256
Cancer Lett. 2001 May 10;166(1):41-6
pubmed: 11295285
Mediators Inflamm. 2015;2015:143941
pubmed: 26504356
J Cell Biochem. 2019 Apr;120(4):5444-5448
pubmed: 30387170
Hum Immunol. 2010 Sep;71(9):905-10
pubmed: 20600447
World J Gastrointest Oncol. 2019 Sep 15;11(9):665-678
pubmed: 31558972
Tumour Biol. 2016 Jan;37(1):405-12
pubmed: 26219901
Oncogene. 2010 Mar 25;29(12):1753-62
pubmed: 20062084
Int J Mol Sci. 2018 Jul 04;19(7):
pubmed: 29973541
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Infect Immun. 2002 Jun;70(6):3149-55
pubmed: 12011009
J Cancer Res Clin Oncol. 2011 Apr;137(4):577-83
pubmed: 20512382
Proc Natl Acad Sci U S A. 1997 Apr 1;94(7):3195-9
pubmed: 9096369
Cell Physiol Biochem. 2005;15(1-4):29-40
pubmed: 15665513
Cancer Res. 2005 Oct 15;65(20):9147-51
pubmed: 16230370
Biochim Biophys Acta. 2011 Mar;1812(3):283-9
pubmed: 21126581
Results Probl Cell Differ. 2009;49:1-15
pubmed: 19137269
Cancer Res. 2013 Jul 1;73(13):4061-74
pubmed: 23794706
Gastroenterology. 2003 Aug;125(2):364-71
pubmed: 12891537
Lung Cancer. 2006 Apr;52(1):15-20
pubmed: 16476505
J Invest Dermatol. 2000 Jun;114(6):1180-3
pubmed: 10844563
Acta Pharmacol Sin. 2008 Nov;29(11):1275-88
pubmed: 18954521
Turk J Gastroenterol. 2017 Jul;28(4):272-282
pubmed: 28699601
J Exp Clin Cancer Res. 2018 Dec 28;37(1):326
pubmed: 30591049
Meta Gene. 2016 Jun 03;9:128-36
pubmed: 27331018
Support Care Cancer. 2020 Feb;28(2):531-540
pubmed: 31076897
J Leukoc Biol. 1999 Oct;66(4):562-6
pubmed: 10534109
Rheumatology (Oxford). 2010 Jul;49(7):1215-28
pubmed: 20194223
Immunogenetics. 1994;39(2):150-4
pubmed: 7903959
Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):47-53
pubmed: 28560288
Microbiol Immunol. 2004;48(9):647-54
pubmed: 15383700
J Biomed Sci. 2017 Dec 04;24(1):90
pubmed: 29202842
Oncogenesis. 2017 Sep 25;6(9):e383
pubmed: 28945218
Biotechnol Biotechnol Equip. 2014 Sep 3;28(5):911-917
pubmed: 26019577
Cancer Res. 2013 Jul 1;73(13):3938-50
pubmed: 23704210